太突然！彻底退出中国市场，知名药企终止供药

Core Insights - Recordati's subsidiary in China, Ruikangdi, has officially filed for deregistration, marking its complete exit from the Chinese market, which will also halt the supply of several rare disease medications [1] - Ruikangdi, established in 2021, focused on rare diseases and had received approval for three rare disease drugs in China [1] - The exit of Ruikangdi is particularly significant for patients with Cushing's syndrome, as it removes the only approved treatment, Phosphate Ozonostatin, which was commercialized in April 2025 [1] Group 1 - Ruikangdi's exit means that patients will no longer have access to a "lifesaving drug," with reports indicating that one patient has spent approximately 1 million yuan on treatment over four years [1] - Phosphate Ozonostatin was priced at around 8,000 yuan per box in China, with an average annual treatment cost of about 200,000 yuan [2] - The drug was expected to be included in the national medical insurance directory, which could have reduced out-of-pocket costs for patients, but ultimately, it was not included [2] Group 2 - The challenges faced in the rare disease sector include limited awareness among patients and doctors, high costs of medical education, and the economic difficulties faced by many families with rare disease patients [3] - Recordati's exit is not an isolated case; BioMarin also withdrew a rare disease treatment from the Chinese market in 2024, highlighting ongoing issues in the sector [3]